Literature DB >> 11605819

Autonomic dysfunction in Lambert-Eaton myasthenic syndrome.

S A Waterman1.   

Abstract

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder characterized by muscle weakness and autonomic dysfunction. Recent ex vivo and in vitro studies demonstrate that autoantibodies to the P/Q-subtype of voltage-gated calcium channel inhibit transmitter release from parasympathetic, sympathetic, and enteric neurons, a mechanism likely to underlie the widespread autonomic dysfunction in LEMS. This review summarizes clinical studies characterizing the autonomic symptoms and signs in LEMS and the effectiveness of treatment in alleviating these symptoms. Serological assays and in vitro pharmacologic and electrophysiologic studies are also discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11605819     DOI: 10.1007/bf02329922

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  48 in total

1.  Calcium channels controlling acetylcholine release in the guinea-pig isolated anterior pelvic ganglion: an electropharmacological study.

Authors:  A B Smith; T C Cunnane
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

2.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

3.  Ocular autonomic nerve function in Lambert-Eaton myasthenic syndrome.

Authors:  C V Clark; J Newsom-Davis; M D Sanders
Journal:  Eye (Lond)       Date:  1990       Impact factor: 3.775

4.  Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment.

Authors:  R W Tim; J M Massey; D B Sanders
Journal:  Neurology       Date:  2000-06-13       Impact factor: 9.910

5.  Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.

Authors:  M Motomura; B Lang; I Johnston; J Palace; A Vincent; J Newsom-Davis
Journal:  J Neurol Sci       Date:  1997-03-20       Impact factor: 3.181

6.  Metabolism of omega-conotoxin-sensitive voltage-operated calcium channels in human neuroblastoma cells: modulation by cell differentiation and anti-channel antibodies.

Authors:  M Passafaro; F Clementi; E Sher
Journal:  J Neurosci       Date:  1992-09       Impact factor: 6.167

7.  Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine.

Authors:  H Lundh; O Nilsson; I Rosén
Journal:  Neurology       Date:  1984-10       Impact factor: 9.910

8.  The Lambert-Eaton myasthenic syndrome. A review of 50 cases.

Authors:  J H O'Neill; N M Murray; J Newsom-Davis
Journal:  Brain       Date:  1988-06       Impact factor: 13.501

9.  Action of Lambert-Eaton myasthenic syndrome IgG at mouse motor nerve terminals.

Authors:  C Prior; B Lang; D Wray; J Newsom-Davis
Journal:  Ann Neurol       Date:  1985-06       Impact factor: 10.422

Review 10.  Immunopathology of the Lambert-Eaton myasthenic syndrome.

Authors:  B Lang; J Newsom-Davis
Journal:  Springer Semin Immunopathol       Date:  1995
View more
  8 in total

1.  Upregulation of L-type calcium channels in colonic inhibitory motoneurons of P/Q-type calcium channel-deficient mice.

Authors:  Eileen Rodriguez-Tapia; Alberto Perez-Medina; Xiaochun Bian; James J Galligan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-01       Impact factor: 4.052

2.  Antineuronal antibodies in idiopathic achalasia and gastro-oesophageal reflux disease.

Authors:  P L Moses; L M Ellis; M R Anees; W Ho; R I Rothstein; J B Meddings; K A Sharkey; G M Mawe
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

3.  Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.

Authors:  Sabine Lindquist; Martin Stangel
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-30       Impact factor: 2.570

4.  Autonomic dysfunction detected by skin sympathetic response in Lambert-Eaton myasthenic syndrome: a case report.

Authors:  Jinghong Zhang; Xusheng Huang; Qiang Shi
Journal:  BMC Neurol       Date:  2022-03-19       Impact factor: 2.474

Review 5.  Similarity and Diversity of Presynaptic Molecules at Neuromuscular Junctions and Central Synapses.

Authors:  Kenji Takikawa; Hiroshi Nishimune
Journal:  Biomolecules       Date:  2022-01-21

6.  Subclinical sympathetic neuropathy appears early in the course of Crohn's disease.

Authors:  Bodil Ohlsson; Göran Sundkvist; Stefan Lindgren
Journal:  BMC Gastroenterol       Date:  2007-08-14       Impact factor: 3.067

7.  Heart rate and blood pressure variability in patients with myasthenia gravis.

Authors:  Chikkulikere Sivan Puneeth; Sadanandavalli Retanaswami Chandra; Ravi Yadav; Talakad Narasappa Sathyaprabha; Sajish Chandran
Journal:  Ann Indian Acad Neurol       Date:  2013-07       Impact factor: 1.383

8.  Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome.

Authors:  Alexander F Lipka; Marion I Boldingh; Erik W van Zwet; Marco W J Schreurs; Jan B M Kuks; Chantal M Tallaksen; Maarten J Titulaer; Jan J G M Verschuuren
Journal:  Neurology       Date:  2019-12-12       Impact factor: 9.910

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.